primarily revolving around promising clinical trial results for Silence Therapeutics’ lead product candidate, zerlasiran. The recent data from the ALPACAR-360 phase II study presented at the American ...
(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback